CD47 and cancer: A CD47 antibody‐conjugated liposome was developed, and cancer cell membrane vesicles (CMV) were adopted to reversibly block the CD47 antibody to relieve the on‐target effect, forming CMV‐anti‐CD47‐Lip (Figure S28A, Supporting Information).